Indivior Pharmaceuticals (INDV) Cash from Financing Activities (2024 - 2026)

Indivior Pharmaceuticals' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 141.18% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was -$6.0 million, a 90.48% increase from a year earlier, with the FY2025 full-year figure at -$30.0 million, up 70.59% from the prior year.
• Cash from Financing Activities rose to $7.0 million in Q1 2026 per INDV's latest filing, from -$5.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $40.0 million in Q4 2024 and bottomed at -$56.0 million in Q1 2024.
• The 3-year median for Cash from Financing Activities is -$5.0 million (2025), against an average of -$13.9 million.
• Across the five-year window, Cash from Financing Activities plunged 112.5% in 2025 and soared 141.18% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $40.0 million in 2024, then plunged by 112.5% to -$5.0 million in 2025, then surged by 240.0% to $7.0 million in 2026.
• Per Business Quant, the three latest INDV Cash from Financing Activities figures stand at $7.0 million (Q1 2026), -$5.0 million (Q4 2025), and -$3.0 million (Q3 2025).